67 results about "Interstitial pneumonia" patented technology

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 2 (PCV2) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV2 infection. Preferably, they include lymphadenopathy, lymphoid depletion and / or multinucleated / giant histiocytes. Moreover, the clinical symptoms include lymphadenopathy in combination with one or a multiple of the following symptoms in pigs: (1) interstitial pneumonia with interlobular edema, (2) cutaneous pallor or icterus, (3) mottled atrophic livers, (4) gastric ulcers, (5) nephritis and (6) reproductive disorders, e.g. abortion, stillbirths, mummies, etc. Furthermore the clinical symptoms include Pia like lesions, normally known to be associated with Lawsonia intracellularis infections.

The present invention relates to a compound represented by the formula (I),wherein all symbols are as defined in the description,a salt thereof, a solvate thereof, or a prodrug thereof, which has a leukotriene receptor antagonistic activity which is expected to be more effective than those of the leukotriene receptor antagonists currently used in clinical trials. Therefore, it is useful as an agent for the prevention and / or treatment of a leukotriene-mediated disease such as a respiratory diseases such as bronchial asthma, chronic obstructive pulmonary disease, pulmonary emphysema, chronic bronchitis, pneumonia (e.g. interstitial pneumonia etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), allergic rhinitis, sinusitis (e.g. acute sinusitis, chronic sinusitis, etc.), or the like, or as an expectorant or an antiitussive.

Disclosed herein are methods, constructs, kits, and the like, which can be used for detecting and / or differentiating interstitial lung disease. For example, idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) can be detected and / or differentiated using at least one biomarker.

The invention relates to compounds of formula (A) and formula (I):or a salt thereof, wherein R1, R2, R10, R11, R12, R13, R14, R15, R16, q and p are as described herein. Compounds of formula (A), formula (I), and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.).Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

Compounds represented by formula (I), prodrugs thereof and salts thereof, and pharmaceutical compositions comprising the same as an active ingredient (wherein each symbol has the meaning as defined in the specification.). Because of having an EDG-1 agonism, the compounds represented by formula (I) are useful in preventing and / or treating peripheral arterial disease such as arteriosclerosis obliterans, thromboangiitis obliterans, Buerger's disease or diabetic neuropathy, sepsis, angiitis, nephritis, pneumonia, stroke, myocardial infarction, edematous state, atherosclerosis, varicosity such as hemorrhoid, anal fissure or fistula ani, dissecting aneurysm of the aorta, angina, DIC, pleuritis, congestive heart failure, multiple organ failure, bedsore, burn, chronic ulcerative colitis, Crohn's disease, heart transplantation, renal transplantation, dermal graft, liver transplantation, osteoporosis, pulmonary fibrosis, interstitial pneumonia, chronic hepatitis, liver cirrhosis, chronic renal failure, or glomerular sclerosis.

This invention is directed to methods of preventing or treating diseases or conditions of the lungs associated with excessive cell proliferation, remodeling, inflammation, vasoconstriction, bronchoconstriction, airway hyperreactivity and edema. Particularly, this invention is directed to methods of treating pulmonary diseases such as asthma; chronic obstructive pulmonary disease; respiratory tract illness caused by respiratory syncytial virus; pulmonary arterial hypertension; acute respiratory distress syndrome and ventilator induced lung injury; cystic fibrosis; bronchiectasis; alpha-1-antitrypsin deficiency; rhinitis; rhinosinusitis; primary ciliary dyskinesia; pneumonia; bronchiolitis caused by agents other than respiratory syncytial virus; and interstitial lung disease including lymphangioleiomyomatosis; idiopathic pulmonary fibrosis; obliterative bronchiolitis or bronchiolitis obliterans organizing pneumonia due to lung transplantation or HSCT; nonspecific interstitial pneumonia; cryptogenic organizing pneumonia; acute interstitial pneumonia; respiratory bronchiolitis-associated interstitial lung disease; or pulmonary sarcoidosis. The method comprises administering to a subject an effective amount of a rho kinase inhibitor compound to treat the disease.

The invention provides a method capable of readily discriminating pathologic conditions and judging selection of a therapeutic drug, the degree of the therapeutic effect, discontinuation of medication, etc., wherein stages quantitatively judged by digitizing substances contained in urine, which is different from conventional methods for judging stages of an ulcerative colitis and an interstitial pneumonitis which are performed by observation of mucous lesions with endoscopy requiring the skill or by analysis of histological samples collected from the living body.The method measures the value of main metabolites of prostaglandin E (PGE-MUM) concentration in urine and judges stages between the pre-remission phase of and the remission phase of ulcerative colitis.The method also measures the value of the PGE-MUM concentration in urine and judges stages between the active phase and the non-active phase of interstitial pneumonitis.

A composite medicine for treating pneumonia, pulmonary fibrosis, cerebral infarction, cardiovascular and cerebrovascular ischemic diseases, ischemic eye disease, etc is prepared from anisodine (0.05-0.4 Wt portions) and procaine (5-40). Its preparing process is also disclosed.

The invention relates to compounds of formula (A):or a salt thereof, wherein R1, R2, R5a, R5b, R6a, R6b, R7a, R7b, R8a, R8b, R9a, R9b, R10a, R10b, R11a, R11b, R21, n, and G are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αVβ6 integrin inhibitors that are useful for treating fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The invention relates to compounds of formula (I): formula (I) or a salt thereof wherein R1, R5, R7, R8, X, m, n, p and q are as described herein. Compounds of formula (I) and pharmaceutical compositions thereof are αvβ6 integrin inhibitors that are useful for treating tissue specific fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP).

The present invention is directed to a method of using compounds of Formula (I) to inhibit Cathepsin B. Specifically the compounds of the present invention are useful as therapeutic agents for the treatment of tumor invasion, metastasis, Alzheimer's Disease, arthritis, inflammatory diseases such as chronic and acute pancreatitis, inflammatory airway disease, and bone and joint disorders, including osteoporosis, osteoarthritis, rheumatoid arthritis, psoriasis, and other autoimmune disorders, liver fibrosis, including liver fibrosis associated with HCV, all types of steatosis (including non-alcoholic steatohepatitis) and alcohol-associated steatohepatitis, non-alcoholic fatty liver disease, forms of pulmonary fibrosis including idiopathic pulmonary fibrosis, pathological diagnosis of interstitial pneumonia following lung biopsy, renal fibrosis, cardiac fibrosis, retinal angiogenesis and fibrosis / gliosis in the eye, schleroderma, and systemic sclerosis. The compounds of Formula (I) are also useful for treating subjects with both HCV and fibrosis in a mammal, particularly liver fibrosis, and subjects affirmatively diagnosed or at risk for both HCV and liver fibrosis.

The invention relates to a complex of biguanide and EGFR (Epidermal growth factor receptor)-TKI (Tyrosine kinase inhibitor) or ALK (anaplastic lymphoma kinase)-TKI and application of the complex. The complex can be used for preventing or relieving interstitial pneumonia and particularly the interstitial pneumonia caused by EGFR-TKI or ALK-TKI during treatment of NSCLC (Non-Small Cell Lung Cancer). The complex can prevent complications caused by EGFR-TKI or ALK-TKI during treatment of NSCLC, thereby effectively improving the treatment effect of EGFR-TKI or ALK-TKI and reducing the occurrence and development of complications of a patient.

As a compound having a potent oral activity and a long-lasting cysLT1 / cysLT2 receptor antagonistic activity, the compound of the formula (I):which exhibits potent antagonistic activity against the cysLT1 / cysLT2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and / or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

The invention discloses a Mo Hsp70 protein based indirect ELISA (enzyme-linked immunosorbent assay) kit and a using method of the Mo Hsp70 protein based indirect ELISA kit. The Mo Hsp70 protein based indirect ELISA kit is prepared from the following raw materials: a Mo Hsp70 protein coated ELISA plate, Mo standard positive serum, Mo standard negative serum, an enzyme-labeled secondary antibody, 50-time PBST buffer solution, block buffer solution, substrate solution A, substrate solution B and stop buffer. The Mo Hsp70 protein based indirect ELISA kit can detect the Mo Hsp70 protein antibody of goat serum, can provide key technology for the early monitoring of interstitial pneumonia of sheep and goats, caused by Mo, the immune effect evaluation of vaccines and correlational research, and has important significance on early detection and early control of epidemic diseases caused by the pathogen.

The invention discloses a traditional Chinese medicine formula for treating interstitial pneumonia. The formula is prepared from cordyceps sinensis, musk, pearl, borneol, poria cum radix pini, radix scutellariae, cortex mori radicis, trichosanthes kirilowii maxim, bulbus fritillariae cirrhosae, bulbus fritillariae thunbergii, pangolin scales, exocarpium citri rubrum, uncaria rhynchophylla and other raw medicinal materials. The traditional Chinese medicine formula has simple composition and natural sources, has good and stable effect on treatment of interstitial pneumonia, has no obvious toxic or side effect and complications, and has simple operation of preparation work.

A composition for preventing or treating inflammatory disease and that is effective for inflammatory disease such as fulminant hepatitis and interstitial pneumonia. For such an objective, the present uses a culture supernatant obtained by culturing dental pulp stem cells as the active ingredient of the composition for preventing or treating inflammatory disease.

Disclosed are biomarkers, methods and assay systems for the identification of poor prognosis of interstitial pneumonia (pulmonary fibrosis) in an individual diagnosed with suspected of having interstitial pneumonia.

The present invention provides a method for detecting idiopathic interstitial pneumonia, which comprises measuring the expression level of a periostin gene or the amount of a periostin protein in a biological sample. Thereby, a method for detecting idiopathic interstitial pneumonia using a marker is provided.

The invention belongs to the field of biological diagnosis and medicine, and particularly relates to an application of a chemotactic factor CCL8 in preparation of a dermatomyositis condition and prognosis evaluation reagent. According to the invention, a patient plasma specimen for definite diagnosis of dermatomyositis is used as a research object; protein chip detection is carried out; a sample is expanded; a protein chip result is verified by an ELISA method; by combining biochemical indexes and clinical manifestation judgment correlation of patients, it is proved that the blood plasma CCL8level of dermatomyositis patients is remarkably higher than that of healthy people, the expression level of the blood plasma CCL8 is related to the illness state and prognosis of the patients, the blood plasma CCL8 level of dermatomyositis patients effective in treatment is remarkably reduced, and CCL8 can aggravate pulmonary lesions of interstitial pneumonia mice. Therefore, the CCL8 can be usedas a potential biomarker to be applied to a reagent for evaluating the illness state and prognosis of dermatomyositis patients, experimental data and theoretical basis are provided for the applicationof the CCL8 to the illness state and prognosis evaluation of the dermatomyositis patients, and the invention further provides a corresponding kit for evaluating the illness state and prognosis of thedermatomyositis patients.

A preventive agent, a diagnostic agent or a therapeutic agent for interstitial pneumonia, which comprises an anti-CCR4 antibody and / or an anti-CXCR3 antibody as an active ingredient, a diagnostic agent for discriminating between usual idiopathic interstitial pneumonia and non-specific idiopathic interstitial pneumonia which comprises an anti-CCR4 antibody and an anti-CXCR3 antibody as an active ingredient, and a method for discriminating between usual idiopathic interstitial pneumonia and non-specific idiopathic interstitial pneumonia, which comprises detecting and / or determining a Th2 cell and a Th1 cell in a sample by using an anti-CCR4 antibody and an anti-CXCR3 antibody.

The invention discloses a soil preparation for preventing and treating diseases related to neuroendocrine dyscrasia. The soil preparation is prepared from soil after sterilization treatment and oral probiotics or auxiliary materials. The invention further discloses a preparation method of the soil preparation. The method comprises the following steps that non-pollution soil is collected, after high-pressure sterilization and cooling are conducted, the soil is uniformly mixed with the probiotics or the auxiliary materials according to a predetermined proportion, and capsules or powder are prepared. The soil preparation prepared by adopting the preparation method can adjust the structural composition of enteric microorganisms, is beneficial for adjusting neuroendocrine of the human body, canbe used for preventing and treating diseases such as primary interstitial cystitis, interstitial pneumonia, primary prosopalgia, multiple sclerosis, alopecia areata, psoriasis, depressive disorder, somnipathy, whelks or constipation, and is high in safety. The raw materials adopted by the soil preparation are sufficient and low in cost, the preparation is simple, and the preparation method is easy to implement.

The invention provides a phlegm reducing traditional Chinese medicine composition. The phlegm reducing traditional medicine composition is prepared from the following raw materials, in parts by weight: 2-12 parts of cortex mori, 1-3 parts of semen brassicae, 1-3 parts of fructus schisandrae, 2-12 parts of fructus perillae, 2-12 parts of semen lepidii, 1-3 parts of rhizoma pinelliae, 2-12 parts ofradix asteris, 1-3 parts of exocarpium citri rubrum and 1-3 parts of radix platycodi. The phlegm reducing traditional Chinese medicine composition achieves the efficacy of phlegm reducing and promoting, reliefs the symptoms of abundant expectoration, coughing, asthma and dyspnea caused by acute and chronic respiratory diseases, further rectifies the phlegm-damp habitus of chronic respiratory diseases, interdicts or delays disease development, and thus achieves the purpose of clinical rehabilitation. The phlegm reducing traditional Chinese medicine composition can be used for treating the diseases such as chronic pharyngitis, chronic bronchitis, bronchial asthma, chronic obstructive pulmonary disease, interstitial pneumonia and pulmonary interstitial fibrosis, has an outstanding curative effect, does not contain chemical synthesis matter, and is suitable for a wide range of groups.

A traditional Chinese medicine for remedying the interstitial pneumonia belongs to the traditional Chinese medicine for remedying the pneumonia. The main prescription is 20 grams of heterophylly falsestarwort roots, 25 grams of milkvetch roots, 15 grams of tubers of dwarf lilyturf, 15 grams of radixes adenophorae, 10 grams of Szechwan fritillary bulbs, 10 grams of peach nuts, 12 grams of angelica roots, 10 grams of safflowers, 12 grams of danshen roots, 12 grams of earthworms, 9 grams of schisandra fruits, 10 grams of stemona roots and 12 grams of white swallowwort. The auxiliary prescriptions are that for with patient with serious pulmonary heat of the symptoms of red tongue, yellow fur, coughing with yellow thick phlegm etc., 10 grams of baical skullcap roots and 30 grams of heartleaf houttuynia herbs are added; for the patient with serious oppression in the chest, 10 grams snakegourd peels of and 10 grams of balloonflower roots are added. The compatibility of the traditional Chinese herbal medicines is simple; the medicines used in the medicine prescription are all natural herbal medicines which can be conveniently gotten and used; the manufacturing method is simple; the curative effect after being taken is good; the medicine price is cheap, and the medicine is especially fit for people who live at the remote small villages away from villages and towns to use. The treatment expense for the patient with the disease of the interstitial pneumonia is low, which solves the treatment problem which is caused by low family income, poor living and lack of local medical treatment condition.

The invention discloses application of an compound of an anti-human CD4 monoclonal antibody and an anti-human CD184 monoclonal antibody serving as markers, in particular relates to application of the anti-human CD4 monoclonal antibody and the anti-human CD184 monoclonal antibody serving as markers for diagnosing connective tissue disease correlated interstitial pneumonia, application of the anti-human CD4 monoclonal antibody and the anti-human CD184 monoclonal antibody to preparation of a reagent or kit for diagnosing the connective tissue disease correlated interstitial pneumonia, or application of the anti-human CD4 monoclonal antibody and the anti-human CD184 monoclonal antibody to preparation of a reagent or kit for judging the severity degree, regression or prognosis of the connective tissue disease correlated interstitial pneumonia. The invention further provides a corresponding kit.